RPSA
MRNA icon

Richard P. Slaughter Associates’s Moderna MRNA Stock Holding History

Richard P. Slaughter Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,901
Closed -$1.26M – 153
2024
Q3 		$1.26M Sell
18,901
-4,817
-20% -$442K 0.29% 86
2024
Q2 		$2.82M Sell
23,718
-730
-3% -$92.4K 0.66% 35
2024
Q1 		$2.61M Sell
24,448
-5,555
-19% -$560K 0.62% 41
2023
Q4 		$2.98M Buy
30,003
+10,036
+50% +$844K 0.74% 26
2023
Q3 		$2.06M Buy
19,967
+3,962
+25% +$442K 0.55% 44
2023
Q2 		$1.94M Buy
16,005
+276
+2% +$36.8K 0.56% 50
2023
Q1 		$2.42M Sell
15,729
-197
-1% -$32.5K 0.79% 30
2022
Q4 		$2.86M Sell
15,926
-23
-0.1% -$3.76K 0.9% 31
2022
Q3 		$1.89M Buy
15,949
+1,934
+14% +$293K 0.79% 41
2022
Q2 		$2M Buy
14,015
+133
+1% +$19K 0.88% 30
2022
Q1 		$2.39M Buy
13,882
+3,192
+30% +$537K 0.88% 35
2021
Q4 		$2.71M Buy
10,690
+5,656
+112% +$1.65M 0.96% 32
2021
Q3 		$1.94M Sell
5,034
-9,034
-64% -$3.33M 0.77% 43
2021
Q2 		$3.31M Buy
+14,068
New +$2.51M 1.28% 19

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Richard P. Slaughter Associates's MRNA Position: Q4 2024 in Review

Richard P. Slaughter Associates sold out of Moderna (MRNA) in Q4 2024, closing a stake of 18,901 shares — an estimated $1.26M sold.

Richard P. Slaughter Associates first reported a position in MRNA in Q2 2021 and held it in 14 quarters. The position peaked at $3.31M in Q2 2021. 747 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Richard P. Slaughter Associates reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Richard P. Slaughter Associates sold 18,901 Moderna shares in Q4 2024, an estimated $1.26M.
  • Richard P. Slaughter Associates first reported a position in Moderna in Q2 2021 and held it in 14 quarters.
  • Richard P. Slaughter Associates's Moderna position peaked at $3.31M in Q2 2021.
  • 747 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Richard P. Slaughter Associates's 13F filing for Q4 2024, filed 14 Jan 2025.